Native T1 mapping for the diagnosis of cardiac amyloidosis in patients with left ventricular hypertrophy.
Male
Humans
Middle Aged
Aged
Aged, 80 and over
Female
Hypertrophy, Left Ventricular
/ diagnostic imaging
Contrast Media
Gadolinium
Cardiomyopathy, Hypertrophic
/ complications
Myocardium
/ pathology
Amyloidosis
/ complications
Heart Diseases
Hypertension
Predictive Value of Tests
Magnetic Resonance Imaging, Cine
Cardiac amyloidosis
Cardiac magnetic resonance
Left ventricular hypertrophy
Native T1 mapping
Journal
Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
02
01
2022
accepted:
03
03
2022
pubmed:
1
4
2022
medline:
14
3
2023
entrez:
31
3
2022
Statut:
ppublish
Résumé
Cardiac magnetic resonance (CMR) with parametric mapping can improve the characterization of myocardial tissue. We studied the diagnostic value of native T1 mapping to detect cardiac amyloidosis in patients with left ventricular (LV) hypertrophy. One hundred twenty-five patients with increased LV wall thickness (≥ 12 mm end-diastole) who received clinical CMR in a 3 T scanner between 2017 and 2020 were included. 31 subjects without structural heart disease served as controls. Native T1 was measured as global mean value from 3 LV short axis slices. The study was registered at German clinical trial registry (DRKS00022048). Mean age of the patients was 66 ± 14 years, 83% were males. CA was present in 24 patients, 21 patients had hypertrophic cardiomyopathy (HCM), 80 patients suffered from hypertensive heart disease (HHD). Native T1 times were higher in patients with CA (1409 ± 59 ms, p < 0.0001) compared to healthy controls (1225 ± 21 ms), HCM (1266 ± 44 ms) and HHD (1257 ± 41 ms). HCM and HHD patients did not differ in their native T1 times but were increased compared to control (p < 0.01). ROC analysis of native T1 demonstrated an area under the curve for the detection of CA vs. HCM and HHD of 0.9938 (p < 0.0001), which was higher than that of extracellular volume (0.9876) or quantitative late gadolinium enhancement (0.9406; both p < 0.0001). The optimal cut-off value of native T1 to diagnose CA was 1341 ms (sensitivity 100%, specificity 97%). Non-contrast CMR imaging with native T1 mapping provides high diagnostic accuracy to diagnose cardiac amyloidosis in patients with left ventricular hypertrophy.
Sections du résumé
BACKGROUND
BACKGROUND
Cardiac magnetic resonance (CMR) with parametric mapping can improve the characterization of myocardial tissue. We studied the diagnostic value of native T1 mapping to detect cardiac amyloidosis in patients with left ventricular (LV) hypertrophy.
METHODS
METHODS
One hundred twenty-five patients with increased LV wall thickness (≥ 12 mm end-diastole) who received clinical CMR in a 3 T scanner between 2017 and 2020 were included. 31 subjects without structural heart disease served as controls. Native T1 was measured as global mean value from 3 LV short axis slices. The study was registered at German clinical trial registry (DRKS00022048).
RESULTS
RESULTS
Mean age of the patients was 66 ± 14 years, 83% were males. CA was present in 24 patients, 21 patients had hypertrophic cardiomyopathy (HCM), 80 patients suffered from hypertensive heart disease (HHD). Native T1 times were higher in patients with CA (1409 ± 59 ms, p < 0.0001) compared to healthy controls (1225 ± 21 ms), HCM (1266 ± 44 ms) and HHD (1257 ± 41 ms). HCM and HHD patients did not differ in their native T1 times but were increased compared to control (p < 0.01). ROC analysis of native T1 demonstrated an area under the curve for the detection of CA vs. HCM and HHD of 0.9938 (p < 0.0001), which was higher than that of extracellular volume (0.9876) or quantitative late gadolinium enhancement (0.9406; both p < 0.0001). The optimal cut-off value of native T1 to diagnose CA was 1341 ms (sensitivity 100%, specificity 97%).
CONCLUSION
CONCLUSIONS
Non-contrast CMR imaging with native T1 mapping provides high diagnostic accuracy to diagnose cardiac amyloidosis in patients with left ventricular hypertrophy.
Identifiants
pubmed: 35355115
doi: 10.1007/s00392-022-02005-2
pii: 10.1007/s00392-022-02005-2
pmc: PMC9998594
doi:
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
334-342Informations de copyright
© 2022. The Author(s).
Références
Maurer MS, Bokhari S, Damy T et al (2019) Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Hear Fail. https://doi.org/10.1161/CIRCHEARTFAILURE.119.006075
doi: 10.1161/CIRCHEARTFAILURE.119.006075
Kittleson MM, Maurer MS, Ambardekar AV et al (2020) Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American heart association. Circulation 142:e7–e22. https://doi.org/10.1161/CIR.0000000000000792
doi: 10.1161/CIR.0000000000000792
pubmed: 32476490
Ruberg FL, Grogan M, Hanna M et al (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73:2872–2891. https://doi.org/10.1016/j.jacc.2019.04.003
doi: 10.1016/j.jacc.2019.04.003
pubmed: 31171094
pmcid: 6724183
Gillmore JD, Maurer MS, Falk RH et al (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133:2404–2412. https://doi.org/10.1161/CIRCULATIONAHA.116.021612
doi: 10.1161/CIRCULATIONAHA.116.021612
pubmed: 27143678
Yilmaz A, Bauersachs J, Bengel F et al (2021) Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK). Clin Res Cardiol 110:479–506. https://doi.org/10.1007/s00392-020-01799-3
doi: 10.1007/s00392-020-01799-3
pubmed: 33459839
pmcid: 8055575
Elliott PM, Anastasakis A, Borger MA et al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733–2779. https://doi.org/10.1093/eurheartj/ehu284
doi: 10.1093/eurheartj/ehu284
pubmed: 25173338
Mahrholdt H, Wagner A, Judd RM et al (2005) Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J 26:1461–1474. https://doi.org/10.1093/eurheartj/ehi258
doi: 10.1093/eurheartj/ehi258
pubmed: 15831557
Ganesan AN, Gunton J, Nucifora G et al (2018) Impact of late gadolinium enhancement on mortality, sudden death and major adverse cardiovascular events in ischemic and nonischemic cardiomyopathy: a systematic review and meta-analysis. Int J Cardiol 254:230–237. https://doi.org/10.1016/j.ijcard.2017.10.094
doi: 10.1016/j.ijcard.2017.10.094
pubmed: 29407096
Messroghli DR, Moon JC, Ferreira VM et al (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2 and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imagin. J Cardiovasc Magn Reson 19:75. https://doi.org/10.1186/s12968-017-0389-8
doi: 10.1186/s12968-017-0389-8
pubmed: 28992817
pmcid: 5633041
Fontana M, Ćorović A, Scully P, Moon JC (2019) Myocardial amyloidosis: the exemplar interstitial disease. JACC Cardiovasc Imaging 12:2345–2356. https://doi.org/10.1016/j.jcmg.2019.06.023
doi: 10.1016/j.jcmg.2019.06.023
pubmed: 31422120
Baggiano A, Boldrini M, Martinez-Naharro A et al (2020) Noncontrast magnetic resonance for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 13:69–80. https://doi.org/10.1016/j.jcmg.2019.03.026
doi: 10.1016/j.jcmg.2019.03.026
pubmed: 31202744
Rudolph A, Abdel-Aty H, Bohl S et al (2009) Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy. Relation to remodeling. J Am Coll Cardiol 53:284–291. https://doi.org/10.1016/j.jacc.2008.08.064
doi: 10.1016/j.jacc.2008.08.064
pubmed: 19147047
Garcia-Pavia P, Rapezzi C, Adler Y et al (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 42:1554–1568. https://doi.org/10.1093/eurheartj/ehab072
doi: 10.1093/eurheartj/ehab072
pubmed: 33825853
pmcid: 8060056
Schulz-Menger J, Bluemke DA, Bremerich J et al (2020) Standardized image interpretation and post-processing in cardiovascular magnetic resonance—2020 update. J Cardiovasc Magn Reson 22:19. https://doi.org/10.1186/s12968-020-00610-6
doi: 10.1186/s12968-020-00610-6
pubmed: 32160925
pmcid: 7066763
Kranzusch R, Aus Dem Siepen F, Wiesemann S et al (2020) Z-score mapping for standardized analysis and reporting of cardiovascular magnetic resonance modified look-locker inversion recovery (MOLLI) T1 data: normal behavior and validation in patients with amyloidosis. J Cardiovasc Magn Reson 22:6. https://doi.org/10.1186/s12968-019-0595-7
doi: 10.1186/s12968-019-0595-7
pubmed: 31955712
pmcid: 6970284
McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42:3599–3726. https://doi.org/10.1093/eurheartj/ehab368
doi: 10.1093/eurheartj/ehab368
pubmed: 34447992
Chatzantonis G, Bietenbeck M, Elsanhoury A et al (2021) Diagnostic value of cardiovascular magnetic resonance in comparison to endomyocardial biopsy in cardiac amyloidosis: a multi-centre study. Clin Res Cardiol 110:555–568. https://doi.org/10.1007/s00392-020-01771-1
doi: 10.1007/s00392-020-01771-1
pubmed: 33170349
Patel AR, Kramer CM (2017) Role of cardiac magnetic resonance in the diagnosis and prognosis of nonischemic cardiomyopathy. JACC Cardiovasc Imaging 10:1180–1193. https://doi.org/10.1016/j.jcmg.2017.08.005
doi: 10.1016/j.jcmg.2017.08.005
pubmed: 28982571
pmcid: 5708889
Hinojar R, Varma N, Child N et al (2015) T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic cardiomyopathy: findings from the international T1 multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. https://doi.org/10.1161/CIRCIMAGING.115.003285
doi: 10.1161/CIRCIMAGING.115.003285
pubmed: 26659373
Martinez-Naharro A, Kotecha T, Norrington K et al (2019) Native T1 and extracellular volume in transthyretin amyloidosis. JACC Cardiovasc Imaging 12:810–819. https://doi.org/10.1016/j.jcmg.2018.02.006
doi: 10.1016/j.jcmg.2018.02.006
pubmed: 29550324
Pan JA, Kerwin MJ, Salerno M (2020) Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis. JACC Cardiovasc Imaging 13:1299–1310. https://doi.org/10.1016/j.jcmg.2020.03.010
doi: 10.1016/j.jcmg.2020.03.010
pubmed: 32498919
pmcid: 7340140
van den Boomen M, Slart RHJA, Hulleman EV et al (2018) Native T1 reference values for nonischemic cardiomyopathies and populations with increased cardiovascular risk: a systematic review and meta-analysis. J Magn Reson Imaging 47:891–912. https://doi.org/10.1002/jmri.25885
doi: 10.1002/jmri.25885
pubmed: 29131444
Jurcuţ R, Onciul S, Adam R et al (2020) Multimodality imaging in cardiac amyloidosis: a primer for cardiologists. Eur Heart J Cardiovasc Imaging 21:833–844. https://doi.org/10.1093/ehjci/jeaa063
doi: 10.1093/ehjci/jeaa063
pubmed: 32393965
Dorbala S, Cuddy S, Falk RH (2019) How to image cardiac amyloidosis: a practical approach. JACC Cardiovasc Imaging 13:1368–1383. https://doi.org/10.1016/j.jcmg.2019.07.015
doi: 10.1016/j.jcmg.2019.07.015
pubmed: 31607664
pmcid: 7148180
Fontana M, Banypersad SM, Treibel TA et al (2014) Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging 7:157–165. https://doi.org/10.1016/j.jcmg.2013.10.008
doi: 10.1016/j.jcmg.2013.10.008
pubmed: 24412190
Robinson AA, Chow K, Salerno M (2019) Myocardial T1 and ECV measurement: underlying concepts and technical considerations. JACC Cardiovasc Imaging 12:2332–2344. https://doi.org/10.1016/j.jcmg.2019.06.031
doi: 10.1016/j.jcmg.2019.06.031
pubmed: 31542529
pmcid: 7008718